Integrated proteomics and phosphoproteomics have revealed that targeting sterol O-acyltransferase 1 (SOAT1) to reduce cholesterol content in plasma membranes presents effective treatment options for early-stage HCC patients, which was further verified in a patient-derived tumor xenograft mouse model [58]. The gene discussed is SOAT1; the disease is neoplasm.